PDCD1 and non-small cell lung carcinoma: By updating survival data grouped by driver gene alterations with sufficient follow-up time, we were able to more accurately assess the contribution of next-generation TKIs and anti–PD-1/PD-L1 antibodies to the survival of patients with NSCLC.